Lexaria Bioscience Corp. - LEXX Earnings per share for the trailing year
The year-over-year EPS (TTM) history for Lexaria Bioscience (LEXX) demonstrates profit dynamics where the indicator reaches 46.10. Lexaria Bioscience (LEXX) is optimizing drug transportation and reducing raw material costs to maintain profitability. The company is currently seeking a major licensee for its patents without mergers, monetizing the DehydraTECH system through partnerships with beverage and medical manufacturers.
%20Lexaria%20Bioscience%20Corp.&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_LEXX_-_Lexaria-Bioscience_-_Net-earnings-per-share-EPS-TTM "LEXX (Lexaria Bioscience) Net earnings per one share for the last twelve months history from 02/11/2024 to 11/12/2026 | 👁️GURU.Markets👁️")
Lexaria - analytical breakdowns and key metrics (LEXX)
- stock price and consensus target price:
- issuer market value details:
- issuer book value statistics:
- company total debt and liquidity indicators:
Debt to Equity Lexaria Bioscience|LEXX - Long-Term Debt to Capital|Current Liabilities to Capital Lexaria Bioscience|LEXX - Company Total Debt|Debt to Book Value Ratio Lexaria Bioscience Corp|LEXX - Company Long-Term Debts|Company Short-Term Debts Lexaria Bioscience|Intermediate Coverage Ratio lexariabioscience.com
- net income and valuation ratios data:
LEXX - Net Profit|Company Profit Forecast Lexaria Bioscience|LEXX - P/E Multiple|Forward P/E Multiple Lexaria Bioscience|LEXX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Lexaria Bioscience Corp|LEXX - Operating profit EBITDA|Earnings per share for the last twelve months Lexaria Bioscience|LEXX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months lexariabioscience.com|LEXX - Earnings per share growth in current year|Expected net earnings per share growth next year Lexaria Bioscience
Fundamental valuation:Lexaria Bioscience Corp., LEXX
Investors must filter out earnings volatility risks by evaluating the trailing twelve-month (TTM) year-over-year (YoY) EPS growth to determine the business's sensitivity to market shocks. For Lexaria Bioscience (LEXX), whose success depends on the licensing of drug delivery systems and partnerships with pharma behemoths, this indicator confirms operational resilience and the fundamental reliability of the model during clinical trial periods.
Competitor analysis for Lexaria Bioscience
haleon.com - Earnings per share for the last four quarters|KVUE: Net earnings per share (EPS TTM)|Verona Pharma PLC - Earnings per share for the trailing year|MENS (Jyong Biotech Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Ligand Corp LGND|Earnings per share for the last twelve months Amneal Pharmaceuticals (AMRX)|PRGO (perrigo.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Alvotech SA ALVO|Liquidia Corp - Earnings per share for the last twelve months|Galapagos Genomics - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ANI Pharmaceuticals Corp|MNKD (MannKind Corporation) - Net earnings per share for the last 12 months|Earnings per share for the last 12 months AMPH|PCRX (Pacira BioSciences, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ARS Pharmaceuticals Inc|Earnings per share for the last twelve months Theravance (TBPH)|AQST (Aquestive Corp) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) SCPH (scPharmaceuticals)|Net earnings per share for the last four quarters Tectonic Therapeutic Inc. (TECX)|Tonix Pharmaceuticals Holding Corp. - Net earnings per share (EPS TTM)|SXTC - Net earnings per share (EPS TTM)|EPRX (eupraxiapharma.com) - Net earnings per share for the last 12 months|BioHarvest Sciences Inc - Earnings per share for the trailing year|EXOZ (eXoZymes Inc) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months ORMP|Net earnings per share (EPS TTM) ENTX|Net earnings per share for the last four quarters MindWalk Holdings, Inc.|Earnings per share for the last twelve months ABVC BioPharma Inc ABVC|Cumberland Corp (CPIX) - Net earnings per one share for the last twelve months|QNTM - Earnings per share for the last twelve months|Net earnings per share for the last four quarters fibrogen.com FGEN|TELO: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Rani Therapeutics Holdings, Inc.|SNYR (Synergy CHC Corp.) - Net earnings per share (EPS TTM)|Rallybio Corp. (RLYB) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) PULM|PTHL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Aptorum Group APM|LYRA: Earnings per share for the last 12 months|Impact BioMedical Inc - Net earnings per share (EPS TTM)|TNF Pharmaceuticals (TNFA) - Net earnings per share for the last 12 months|YCBD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months painreform.com (PRFX)|Earnings per share for the last twelve months Altamira Therapeutics Ltd|Earnings per share for the last twelve months LIPO|Net earnings per share (EPS TTM) OPTN|PIRS - Net earnings per one share for the last twelve months|Procaps Group S.A. - Net earnings per share for the last 12 months|PTPI: Earnings per share for the last 12 months|QLI: Net earnings per share for the last 12 months|SLRN (Acelyrin Inc.) - Earnings per share for the last 12 months|TFF Pharma (TFFP) - Earnings per share for the last twelve months
